Item 1. Financial Statements
Item 1. Financial Statements
H.B. FULLER COMPANY AND SUBSIDIARIES
Consolidated Statements of Income
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended
Six Months Ended
May 31,
June 1,
May 31,
June 1,
2025
2024
2025
2024
Net revenue
$
898,095
$
917,107
$
1,686,758
$
1,727,525
Cost of sales
( 611,711
)
( 635,055
)
( 1,173,299
)
( 1,206,237
)
Gross profit
286,384
282,052
513,459
521,288
Selling, general and administrative expenses
( 186,340
)
( 181,456
)
( 366,968
)
( 353,817
)
Other income, net
7,141
3,634
10,347
5,135
Interest expense
( 34,865
)
( 32,314
)
( 66,906
)
( 64,216
)
Interest income
854
1,199
1,954
2,506
Income before income taxes and income from equity method investments
73,174
73,115
91,886
110,896
Income taxes
( 32,726
)
( 22,418
)
( 38,671
)
( 30,231
)
Income from equity method investments
1,397
600
1,894
1,644
Net income including non-controlling interest
41,845
51,297
55,109
82,309
Net income attributable to non-controlling interest
( 17
)
( 33
)
( 33
)
( 54
)
Net income attributable to H.B. Fuller
$
41,828
$
51,264
$
55,076
$
82,255
Earnings per share attributable to H.B. Fuller common stockholders:
Basic
$
0.77
$
0.93
$
1.01
$
1.50
Diluted
$
0.76
$
0.91
$
0.99
$
1.45
Weighted-average common shares outstanding:
Basic
54,443
54,946
54,721
54,824
Diluted
54,952
56,636
55,490
56,604
See accompanying Notes to Unaudited Consolidated Financial Statements.
4
Table of Contents
H.B. FULLER COMPANY AND SUBSIDIARIES
Consolidated Statements of Comprehensive Income
(In thousands)
(Unaudited)
Three Months Ended
Six Months Ended
May 31,
June 1,
May 31,
June 1,
2025
2024
2025
2024
Net income including non-controlling interest
$
41,845
$
51,297
$
55,109
$
82,309
Other comprehensive income (loss)
Foreign currency translation
123,650
( 26,926
)
102,664
( 46,288
)
Defined benefit pension plans adjustment, net of tax
141
419
271
2,538
Interest rate swaps, net of tax
( 2,426
)
10,196
( 3,573
)
7,731
Net investment hedges, net of tax
( 45,449
)
123
( 38,455
)
3,913
Other comprehensive income (loss)
75,916
( 16,188
)
60,907
( 32,106
)
Comprehensive income
117,761
35,109
116,016
50,203
Less: Comprehensive income attributable to non-controlling interest
65
1
98
13
Comprehensive income attributable to H.B. Fuller
$
117,696
$
35,108
$
115,918
$
50,190
See accompanying Notes to Unaudited Consolidated Financial Statements.
5
Table of Contents
H.B. FULLER COMPANY AND SUBSIDIARIES
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
May 31,
November 30,
2025
2024
Assets
Current assets:
Cash and cash equivalents
$ 96,785 $ 169,352
Trade receivables (net of allowances of $ 10,978 and $ 11,621 , as of May 31, 2025 and November 30, 2024, respectively)
584,026 558,336
Inventories
495,588 467,498
Other current assets
118,176 104,019
Total current assets
1,294,575 1,299,205
Property, plant and equipment
1,861,936 1,864,558
Accumulated depreciation
( 994,409 ) ( 982,631 )
Property, plant and equipment, net
867,527 881,927
Goodwill
1,670,078 1,532,221
Other intangibles, net
847,699 770,226
Other assets
452,578 449,665
Total assets
$ 5,132,457 $ 4,933,244
Liabilities, non-controlling interest and total equity
Current liabilities
Notes payable
$ - $ 587
Trade payables
481,957 491,435
Accrued compensation
85,008 106,005
Income taxes payable
27,672 24,225
Other accrued expenses
97,490 97,038
Total current liabilities
692,127 719,290
Long-term debt
2,112,428 2,010,052
Accrued pension liabilities
55,017 51,755
Other liabilities
396,900 322,299
Total liabilities
$ 3,256,472 $ 3,103,396
Commitments and contingencies (Note 13)
Equity
H.B. Fuller stockholders' equity:
Preferred stock ( no shares outstanding) shares authorized – 10,045,900
- -
Common stock, par value $ 1.00 per share, shares authorized – 160,000,000 , shares outstanding – 53,952,793 and 54,657,103 as of May 31, 2025 and November 30, 2024, respectively
$ 53,953 $ 54,657
Additional paid-in capital
278,513 322,636
Retained earnings
1,954,785 1,924,761
Accumulated other comprehensive loss
( 412,553 ) ( 473,395 )
Total H.B. Fuller stockholders' equity
1,874,698 1,828,659
Non-controlling interest
1,287 1,189
Total equity
1,875,985 1,829,848
Total liabilities, non-controlling interest and total equity
$ 5,132,457 $ 4,933,244
See accompanying Notes to Unaudited Consolidated Financial Statements.
6
Table of Contents
H.B. FULLER COMPANY AND SUBSIDIARIES
Consolidated Statements of Total Equity
(In thousands)
(Unaudited)
H.B. Fuller Company Shareholders
Accumulated
Additional
Other
Common
Paid-in
Retained
Comprehensive
Non-Controlling
Stock
Capital
Earnings
Income (Loss)
Interest
Total
Balance at November 30, 2024
$
54,657
$
322,636
$
1,924,761
$
( 473,395
)
$
1,189
$
1,829,848
Comprehensive income (loss)
-
-
13,248
( 15,026
)
33
( 1,745
)
Dividends
-
-
( 12,285
)
-
-
( 12,285
)
Stock option exercises
33
1,351
-
-
-
1,384
Share-based compensation plans and other, net
229
5,307
-
-
-
5,536
Repurchases of common stock
( 729
)
( 43,648
)
-
-
-
( 44,377
)
Balance at March 1, 2025
$
54,190
$
285,646
$
1,925,724
$
( 488,421
)
$
1,222
$
1,778,361
Comprehensive income
-
-
41,828
75,868
65
117,761
Dividends
-
-
( 12,767
)
-
-
( 12,767
)
Stock option exercises
32
1,060
-
-
-
1,092
Share-based compensation plans and other, net
33
7,793
-
-
-
7,826
Repurchases of common stock
( 302
)
( 15,986
)
-
-
-
( 16,288
)
Balance at May 31, 2025
$
53,953
$
278,513
$
1,954,785
$
( 412,553
)
$
1,287
$
1,875,985
H.B. Fuller Company Shareholders
Accumulated
Additional
Other
Common
Paid-in
Retained
Comprehensive
Non-Controlling
Stock
Capital
Earnings
Income (Loss)
Interest
Total
Balance at December 2, 2023
$
54,093
$
301,485
$
1,842,507
$
( 442,880
)
$
708
$
1,755,913
Comprehensive income (loss)
-
-
30,991
( 15,909
)
12
15,094
Dividends
-
-
( 11,246
)
-
-
( 11,246
)
Stock option exercises
200
8,777
-
-
-
8,977
Share-based compensation plans and other, net
225
5,490
-
-
-
5,715
Repurchases of common stock
( 80
)
( 6,128
)
-
-
-
( 6,208
)
Balance at March 2, 2024
$
54,438
$
309,624
$
1,862,252
$
( 458,789
)
$
720
$
1,768,245
Comprehensive income (loss)
-
-
51,264
( 16,156
)
1
35,109
Dividends
-
-
( 12,144
)
-
-
( 12,144
)
Stock option exercises
189
9,123
-
-
-
9,312
Share-based compensation plans other, net
81
7,111
-
-
-
7,192
Repurchases of common stock
( 200
)
( 15,400
)
-
-
-
( 15,600
)
Balance at June 1, 2024
$
54,508
$
310,458
$
1,901,372
$
( 474,945
)
$
721
$
1,792,114
See accompanying Notes to Unaudited Consolidated Financial Statements.
7
Table of Contents
H.B. FULLER COMPANY AND SUBSIDIARIES
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
Six Months Ended
May 31, 2025
June 1, 2024
Cash flows from operating activities:
Net income including non-controlling interest
$
55,109
$
82,309
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities:
Depreciation
44,837
45,099
Amortization
42,443
39,574
Deferred income taxes
( 14,068
)
( 24,117
)
Income from equity method investments, net of dividends received
( 1,894
)
( 1,644
)
Loss on the sale of a business
1,515
-
Loss on impairment of intangible asset
478
-
Gain on sale or disposal of assets
( 101
)
( 166
)
Share-based compensation
12,003
11,930
Pension and other post-retirement benefit plan activity
( 4,493
)
( 4,370
)
Change in assets and liabilities, net of effects of acquisitions:
Trade receivables, net
( 28,942
)
22,639
Inventories
( 40,182
)
( 56,512
)
Other assets
( 4,106
)
( 22,328
)
Trade payables
11,602
38,781
Accrued compensation
( 23,494
)
( 16,424
)
Other accrued expenses
1,097
( 7,002
)
Income taxes payable
( 10,587
)
( 11,218
)
Other liabilities
24,804
( 1,786
)
Foreign currency remeasurement
( 8,252
)
34,210
Net cash provided by operating activities
57,769
128,975
Cash flows from investing activities:
Purchased property, plant and equipment
( 64,534
)
( 90,181
)
Purchased businesses, net of cash acquired
( 162,032
)
( 254,287
)
Purchase of cost method investment
( 2,549
)
-
Proceeds from sale of property, plant and equipment
1,438
694
Proceeds from the sale of a business
75,727
-
Net cash used in investing activities
( 151,950
)
( 343,774
)
Cash flows from financing activities:
Proceeds from issuance of long-term debt
784,900
1,497,000
Repayment of long-term debt
( 687,751
)
( 1,305,500
)
Payment of debt issuance costs
( 1,047
)
( 3,493
)
Net payment of notes payable
( 588
)
( 376
)
Dividends paid
( 24,864
)
( 23,295
)
Proceeds from stock options exercised
2,475
18,289
Repurchases of common stock
( 60,664
)
( 21,809
)
Net cash provided by financing activities
12,461
160,816
Effect of exchange rate changes on cash and cash equivalents
9,153
( 10,647
)
Net change in cash and cash equivalents
( 72,567
)
( 64,630
)
Cash and cash equivalents at beginning of period
169,352
179,453
Cash and cash equivalents at end of period
$
96,785
$
114,823
See accompanying Notes to Unaudited Consolidated Financial Statements.
8
Table of Contents
H.B. FULLER COMPANY AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Amounts in thousands, except per share amounts)
(Unaudited)
Note 1: Basis of Presentation
Overview
The accompanying unaudited interim Consolidated Financial Statements of H.B. Fuller Company and Subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the instructions to Form 10 -Q and Article 10 of Regulation S- X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial position and cash flows in conformity with U.S. generally accepted accounting principles. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments of a normal recurring nature considered necessary for the fair presentation of the results for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.
The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from these estimates. These unaudited interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in our Annual Report on Form 10 -K for the year ended November 30, 2024 as filed with the Securities and Exchange Commission.
New Accounting Pronouncements
In November 20 24, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2024 - 03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220 - 40 ): Disaggregation o f Income Statement Expenses, which requires additional disclosure of the nature of expenses included in our Consolidated Financial Statements. Our effective date of this ASU is our fiscal year ending December 2, 2028. We are evaluating the effect this guidance will have on our Consolidated Finance Statements.
In December 2023, the FASB issued ASU No. 2023 - 09, Income Taxes (Topic 740 ): Improvements to Income Tax Disclosures. This ASU requires entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. Our effective date of this ASU is our fiscal year ending November 28, 2026. We are evaluating the effect that this guidance will have on our Consolidated Financial Statements.
In November 2023, the FASB issued ASU No. 2023 - 07, Segment Reporting (Topic 280 ): Improvements to Reportable Segment Disclosures. This ASU requires enhanced disclosures regarding significant segment expenses and other segment items. The guidance requires public entities to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Our effective date of this ASU is our fiscal year ending November 29, 2025. We are evaluating the effect that this guidance will have on our Consolidated Financial Statements.
Recently issued accounting standards or pronouncements not disclosed above have been excluded as they are not relevant to the company.
Supplier Finance Program
We have agreements with third parties to provide supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated third -party financial institutions. Participating suppliers may, at their sole discretion, elect to finance one or more payment obligations of the Company prior to their scheduled due dates at a discounted price to participating financial institutions. The Company has no economic interest in the sale of these suppliers’ receivables and no direct financial relationship with the financial institutions concerning these services. The Company’s obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers’ decisions to finance amounts under these arrangements. The outstanding payment obligations that were confirmed as valid and remained outstanding as of May 31, 2025, and November 30, 2024, were approxi mately $ 6,485 and $ 5,233 , respectively. These obligations under the Company’s supplier finance programs are included in Accounts payable in the Consolidated Balance Sheets, and the associated payments are reflected in the cash flows from operating activities section of the Consolidated Statements of Cash Flows.
9
Table of Contents
Note 2: Acquisitions and Divestiture
ND Industries Asia, Inc.
On
February 15, 2025, we acquired the assets of ND Industries Asia, Inc. ("ND Industries Taiwan") for a purchase price of
266,960 Taiwan dollar, or approximately
$ 8,160 which was funded through existing cash. This includes a holdback amount of
5,978 Taiwan dollar paid on the
4 -month anniversary of the closing date. Headquartered in Kaohsiung, Taiwan, ND Industries Taiwan is a leading provider of specialty adhesives and fastener locking and sealing solutions. The acquisition of ND Industries Taiwan is expected to accelerate the realization of our top growth priorities in Greater Asia, consistent with our strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer industry. The acquisition fair value measurement was preliminary as of
May 31, 2025 and includes goodwill of
$ 2,320 , other intangible assets of
$ 2,400 and other net assets of
$ 3,440 . Goodwill represents expected synergies from combining ND Industries Taiwan with our existing business. Goodwill is deductible for tax purposes. ND Industries Taiwan is included in our Engineering Adhesives operating segment.
GEM S.r.l. and Medifill Limited
On January 15, 2025, we completed the acquisition of GEM S.r.l. (“GEM”) and on December 2, 2024, we completed the acquisition of Medifill Limited (Medifill") for a total purchase price of 192,130 Euros, or approximately $ 197,260 which was funded through borrowings on our credit facility and existing cash. Included in the purchase price is a holdback to be paid in three annual tranches beginning one year after the date of acquisition. The fair value of the holdback was 28,170 Euros or approximately $28,922 at the date of acquisition. See Note 12 for more information on the fair value of the holdback.
Although they were independent transactions, the acquisitions of GEM and Medifill were accounted for as a single business combination under ASC 805, as they were negotiated concurrently and are economically interdependent. Headquartered in Viareggio, Italy, GEM develops, produces and sells medical adhesives for wound closure in both surgical and topical applications. Headquartered in Dublin, Ireland, Medifill produces medical-grade cyanoacrylate adhesives tailored to the wound closure market for GEM. The acquisitions of GEM and Medifill establish a European headquarters for our Medical Adhesives Technologies business and European production capabilities for our medical adhesive offerings, further shifting our portfolio toward highly profitable, higher growth markets. The acquisition fair value measurement was preliminary as of May 31, 2025 and includes goodwill of $ 92,653 , other intangible assets of $ 105,237 and other net liabilities of $ 630 . G oodwill represents expected synergies from combining GEM and Medifill with our existing business. Goodwill is not deductible for tax purposes. GEM and Medifill are included in our Hygiene, Health and Consumable Adhesives operating segment.
HS Butyl Limited
On August 5, 2024, we acquired HS Butyl Limited (“HS Butyl”) for a purchase price of 18,148 British pound sterling, or approximat ely $ 23,180 which was funded through existing cash. This includes a holdback amount of 2,700 British pound sterling that will be paid on the 18 -month anniversary of the closing date. HS Butyl, headquartered in Lymington, England, is the United Kingdom's largest manufacturer and distributor of high-quality butyl tapes, which provide strong, permanent, watertight seals for a wide variety of applications within the construction, infrastructure, automotive and renewable energy industries. The acquisition of HS Butyl establishes our presence in the European waterproofing tape market, expanding our position as a solution provider to existing customers. It also expands our relevance to more markets and creates opportunities to deliver new, in-demand solutions for our customers, given the technology's relevance to multiple high-value applications. The acquisition fair value measurement was preliminary as of May 31, 2025 and includes other intangible assets of $ 6,974 , goodwill of $ 2,812 and other net assets of $ 13,394 . G oodwill represents expected synergies from combining HS Butyl with our existing business. Goodwill is not deductible for tax purposes. HS Butyl is included in our Building Adhesive Solutions operating segment.
10
Table of Contents
ND Industries, Inc.
On May 20, 2024, we acquired the assets of ND Industries, Inc. (“ND Industries”) for a base purchase price of $ 254,037 which was funded through borrowings on our credit facility and existing cash. ND Industries, headquartered in Clawson, Michigan, is a leading provider of specialty adhesives and fastener locking and sealing solutions serving customers in the automotive, electronics, aerospace and other industries. The acquisition of ND Industries is expected to accelerate the realization of our top growth priorities, consistent with our strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer industry. The acquisition fair value measurement was final as of March 1, 2025 . ND Industries is included in our Engineering Adhesives operating segment.
The following table summarizes the fair value measurement of the assets acquired and liabilities assumed as of the date of acquisition:
Amounts
Current assets
$ 17,085
Property, plant and equipment
26,044
Goodwill
81,268
Other intangibles
Customer relationships
110,100
Trademarks/trade names
8,700
Technology
13,600
Other assets
13
Current liabilities
( 2,773 )
Total
$ 254,037
The expected useful lives of the acquired intangible assets are 15 years for technology, 13 years for customer relationships and ten years for trademarks and tradenames. Based on the fair value measurement of the assets acquired and liabilities assumed, we a llocated $ 81,268 to goo dwill for the expected synergies from combining ND Industries with our existing business. Such goodwill is deductible for tax purposes. The goodwill was assigned to our Engineering Adhesives operating segment.
11
Table of Contents
All acquisitions, individually and in the aggregate, are
not material and therefore pro forma financial information is
not provided.
Divestiture
North America Flooring
On December 2, 2024, we completed the sale of certain assets in our North American Flooring business, which was included in our Construction Adhesives segment for $ 75,727 . The net book value of the assets sold was $ 77,242 which resulted in a $ 1,515 loss. The loss on sale is recorded in other income net , in the Consolidated Statements of Income for the six months ended May 31, 2025.
12
Table of Contents
Note 3: Restructuring Actions
During fiscal year 2023, the Company approved restructuring plans (the "Plans") related to organizational changes and other actions to optimize operations and integrate acquired businesses. The Plans were implemented in the second quarter of fiscal year 2023 and are currently expected to be completed during fiscal year 2026. In implementing the Plans, the Company currently expects to incur pre-tax costs of approx imately $ 70,000 to $ 75,000 for severa nce and related employee costs globally, other restructuring costs related to the streamlining of processes and the payment of anticipated income taxes in certain jurisdictions related to the Plans.
The following table summarizes the pre-tax distribution of charges under these restructuring plans by income statement classification:
Three Months Ended
Six Months Ended
May 31, 2025
June 1, 2024
May 31, 2025
June 1, 2024
Cost of sales
$ ( 19 ) $ 1,279 $ 2,935 $ 4,194
Selling, general and administrative
2,195 1,279 2,752 2,444
$ 2,176 $ 2,558 $ 5,687 $ 6,638
The restructuring charges are all recorded in Corporate Unallocated for segment reporting purposes.
A summary of the restructuring liability is presented below:
Employee-Related
Asset-Related
Other
Total
Balance at December 2, 2023
$ 11,723 $ - $ - $ 11,723
Expenses incurred
13,477 4,673 3,936 22,086
Non-cash charges
- ( 4,673 ) ( 3,925 ) ( 8,598 )
Cash payments
( 16,427 ) - ( 11 ) ( 16,438 )
Foreign currency translation
( 343 ) - - ( 343 )
Balance at November 30, 2024
$ 8,430 $ - $ - $ 8,430
Expenses incurred
3,143 ( 60 ) 2,604 5,687
Non-cash charges
- 60 ( 82 ) ( 22 )
Cash payments
( 7,298 ) - ( 2,522 ) ( 9,820 )
Foreign currency translation
218 - - 218
Balance at May 31, 2025
$ 4,493 $ - $ - $ 4,493
Non-cash charges primarily include accelerated depreciation resulting from the cessation of use of certain long-lived assets and the recording of an inventory provision related to the discontinuance of certain products. Restructuring liabilities have been classified as a component of other accrued expenses on the Consolidated Balance Sheets.
13
Table of Contents
Note 4: Inventories
The composition of inventories is as follows:
May 31,
November 30,
2025
2024
Raw materials
$
224,462
$
215,936
Finished goods
271,126
251,562
Total inventories
$
495,588
$
467,498
Note 5: Goodwill and Other Intangible Assets
The goodwill activity by reportable segment for the six months ended May 31, 2025 is presented below:
Hygiene, Health Building
and Consumable
Engineering
Adhesive
Adhesives
Adhesives
Solutions
Total
Balance at November 30, 2024
$ 399,513 $ 581,344 $ 551,364 $ 1,532,221
Acquisitions
92,032 2,538 ( 1,854 ) 92,716
Foreign currency translation effect
24,533 18,400 2,208 45,141
Balance at May 31, 2025
$ 516,078 $ 602,282 $ 551,718 $ 1,670,078
As discussed in Note 14, as of the beginning of fiscal year 2025, we realigned our operating segment structure with the renamed Building Adhesive Solutions segment, which includes all of the former Construction Adhesives goodwill. A portion of the Engineering Adhesives goodwill was reclassified to the Building Adhesive Solutions segment based on the relative fair value approach.
Balances of amortizable identifiable intangible assets, excluding goodwill and other non-amortizable intangible assets, are as follows:
May 31, 2025
Purchased
Technology
Customer
Amortizable Intangible Assets
and Patents
Relationships
Trade Names
Other
Total
Original cost
$ 222,563 $ 996,945 $ 81,148 $ 7,935 $ 1,308,591
Accumulated amortization
( 43,583 ) ( 382,659 ) ( 30,756 ) ( 3,894 ) ( 460,892 )
Net identifiable intangibles
$ 178,980 $ 614,286 $ 50,392 $ 4,041 $ 847,699
November 30, 2024
Purchased
Technology
Customer
Amortizable Intangible Assets
and Patents
Relationships
Trade Names
Other
Total
Original cost
$ 145,313 $ 1,063,210 $ 67,280 $ 10,031 $ 1,285,834
Impairment
( 343 ) ( 5,616 ) ( 150 ) $ ( 6,109 )
Accumulated amortization
( 55,398 ) ( 418,805 ) ( 28,745 ) ( 7,012 ) ( 509,960 )
Net identifiable intangibles
$ 89,572 $ 638,789 $ 38,385 $ 3,019 $ 769,765
Amortization expense with respect to amortizable intangible assets was $ 21,563 and $ 19,219 for the three months ended May 31, 2025 and June 1, 2024 , respectively, and was $ 42,443 and $ 39,574 for the six months ended May 31, 2025 and June 1, 2024 , respectively.
Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets for the next five fiscal years is as follows:
Remainder
Fiscal Year
2025
2026
2027
2028
2029
Thereafter
Amortization expense
$ 49,696 $ 103,305 $ 101,943 $ 103,153 $ 97,740 $ 391,862
14
Table of Contents
The above amortization expense forecast is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, potential impairment, accelerated amortization or other events.
Non-amortizable intangible assets as of May 31, 2025 and November 30, 2024 were $ 0 and $ 461 , respectively, and relate to trademarks and trade names. The change in non-amortizable assets as of May 31, 2025 compared to November 30, 2024 was due to impairment.
Note 6: Long-Term Debt
On March 6, 2025, we entered into a Refinancing Amendment (the “Refinancing Amendment”), which amended the Second Amended and Restated Credit Agreement dated as of February 15, 2023, as previously amended. Pursuant to the Refinancing Amendment under the Credit Agreement, the outstanding $ 986,545 principal amount of Term B loans (the “Amended TLB”) were refinanced. Furthermore, the interest rate margins applicable to the Amended TLB were decreased by 25 basis points ( 0.25 percent per annum) to 175 basis points for SOFR loans and 75 basis points for prime rate loans. Interest on Term Loan B borrowings is payable at SOFR plus an interest rate spread of 175 basis points with a SOFR floor of 50 basis points ( 6.10 percent at May 31, 2025). The maturity date of February 15, 2030 remains unchanged. The commitment fee rates and interest rates applicable to the revolving credit facility and the Term Loan A facility remain unchanged.
Note 7: Components of Net Periodic Benefit related to Pension and Other Postretirement Benefit Plans
Three Months Ended May 31, 2025 and June 1, 2024
Other
Pension Benefits
Postretirement
U.S. Plans
Non-U.S. Plans
Benefits
Net periodic (benefit) cost:
2025
2024
2025
2024
2025
2024
Service cost
$
-
$
-
$
385
$
347
$
-
$
-
Interest cost
3,242
3,464
1,495
1,560
249
291
Expected return on assets
( 5,717
)
( 6,555
)
( 1,685
)
( 1,627
)
( 3,484
)
( 2,727
)
Amortization:
Prior service cost
-
-
29
16
-
-
Actuarial loss
1,953
1,159
490
510
( 2,277
)
-
Net periodic (benefit) cost
$
( 522
)
$
( 1,932
)
$
714
$
806
$
( 5,512
)
$
( 2,436
)
Six Months Ended May 31, 2025 and June 1, 2024
Other
Pension Benefits
Postretirement
U.S. Plans
Non-U.S. Plans
Benefits
Net periodic (benefit) cost:
2025
2024
2025
2024
2025
2024
Service cost
$
-
$
-
$
753
$
697
$
-
$
-
Interest cost
6,484
6,928
2,937
3,129
498
583
Expected return on assets
( 11,434
)
( 13,110
)
( 3,309
)
( 3,264
)
( 6,968
)
( 5,454
)
Amortization:
Prior service cost
-
-
56
32
-
-
Actuarial loss
3,906
2,318
965
1,024
( 4,554
)
-
Net periodic (benefit) cost
$
( 1,044
)
$
( 3,864
)
$
1,402
$
1,618
$
( 11,024
)
$
( 4,871
)
Service cost is included with employee compensation cost in cost of sales and selling, general and administrative expenses in the Consolidated Statements of Income. The components of our net periodic defined benefit pension and postretirement benefit costs other than service cost are presented in other income, net in the Consolidated Statements of Income.
15
Table of Contents
Note 8: Accumulated Other Comprehensive Income (Loss)
The following table provides details of total comprehensive income (loss):
Three Months Ended May 31, 2025
Three Months Ended June 1, 2024
Non-
Non-
controlling
controlling
H.B. Fuller Stockholders
Interest
H.B. Fuller Stockholders
Interest
Pre-tax
Tax
Net
Net
Pre-tax
Tax
Net
Net
Net income attributable to H.B. Fuller and non-controlling interest
$ 41,828 $ 17 $ 51,264 $ 33
Foreign currency translation¹
$ 123,602 $ - 123,602 48 $ ( 26,894 ) $ - ( 26,894 ) ( 32 )
Defined benefit pension plans adjustment²
194 ( 53 ) 141 - 555 ( 136 ) 419 -
Interest rate swaps³
( 3,206 ) 780 ( 2,426 ) - 13,493 ( 3,297 ) 10,196 -
Net investment hedges³
( 60,068 ) 14,619 ( 45,449 ) - 163 ( 40 ) 123 -
Other comprehensive income (loss)
$ 60,522 $ 15,346 $ 75,868 $ 48 $ ( 12,683 ) $ ( 3,473 ) $ ( 16,156 ) $ ( 32 )
Comprehensive income
$ 117,696 $ 65 $ 35,108 $ 1
Six Months Ended May 31, 2025
Six Months Ended June 1, 2024
Non-
Non-
controlling
controlling
H.B. Fuller Stockholders
Interest
H.B. Fuller Stockholders
Interest
Pretax
Tax
Net
Net
Pretax
Tax
Net
Net
Net income attributable to H.B. Fuller and non-controlling interest
$
55,076
$
33
$
82,255
$
54
Foreign currency translation adjustment¹
$
102,599
$
-
102,599
65
$
( 165,302
)
$
-
( 46,247
)
( 41
)
Defined benefit pension plans adjustment²
373
( 102
)
271
-
3,376
( 838
)
2,538
-
Interest rate swap³
( 4,722
)
1,149
( 3,573
)
-
10,217
( 2,486
)
7,731
-
Net investment hedges³
( 50,824
)
12,369
( 38,455
)
-
5,188
( 1,275
)
3,913
-
Other comprehensive income (loss)
$
47,426
$
13,416
$
60,842
$
65
$
( 146,521
)
$
( 4,599
)
$
( 32,065
)
$
( 41
)
Comprehensive income
$
115,918
$
98
$
50,190
$
13
1 Income taxes are not provided for foreign currency translation relating to indefinite investments in international subsidiaries.
2 Amounts reclassified from accumulated other comprehensive loss into earnings as part of net periodic cost related to pension and other postretirement benefit plans is reported in cost of sales and other income, net.
3 Amounts reclassified from accumulated other comprehensive loss into earnings is reported in other income, net.
The components of accumulated other comprehensive loss are as follows:
May 31, 2025
Non-
H.B. Fuller
controlling
Total
Stockholders
Interest
Foreign currency translation adjustment
$ ( 219,650 ) $ ( 219,199 ) $ ( 451 )
Defined benefit pension plans adjustment, net of taxes of $ 54,442
( 88,760 ) ( 88,760 ) -
Interest rate swap, net of taxes of $ 3,318
( 10,317 ) ( 10,317 ) -
Net investment hedges, net of taxes of $ 24,425
( 75,936 ) ( 75,936 ) -
Reclassification of AOCI tax effects
( 18,341 ) ( 18,341 ) -
Accumulated other comprehensive loss
$ ( 413,004 ) $ ( 412,553 ) $ ( 451 )
November 30, 2024
Non-
H.B. Fuller
controlling
Total
Stockholders
Interest
Foreign currency translation adjustment
$ ( 322,184 ) $ ( 321,798 ) $ ( 386 )
Defined benefit pension plans adjustment, net of taxes of $ 54,545
( 89,031 ) ( 89,031 ) -
Interest rate swap, net of taxes of $ 2,169
( 6,744 ) ( 6,744 ) -
Net investment hedges, net of taxes of $ 12,056
( 37,481 ) ( 37,481 ) -
Reclassification of AOCI tax effects
( 18,341 ) ( 18,341 ) -
Accumulated other comprehensive loss
$ ( 473,781 ) $ ( 473,395 ) $ ( 386 )
16
Table of Contents
Note 9: Income Taxes
Income tax expense for the three and six months ended May 31, 2025 includes $ 13,961 of discrete tax expense and $ 14,952 of discrete tax expense, respectively, relating to the impact of withholding tax recorded on earnings that are no longer permanently reinvested as well as other various U.S. and foreign tax matters. Excluding the discrete tax expense, the overall effective tax rate was 25.7 percent and 25.8 percent for the three and six months ended May 31, 2025 , respectively.
Income tax expense for the three and six months ended June 1, 2024 includes $ 1,317 of discrete tax expense and $ 1,210 of discrete tax benefit, respectively, relating to various foreign tax matters, as well as an excess tax benefit related to U.S. stock compensation. Excluding the discrete tax expense and benefit, the overall effective tax rate was 28.9 percent and 28.4 percent for the three and six months ended June 1, 2024 , respectively.
As of May 31, 2025 , we had a liability of $ 19,415 recorded for gross unrecognized tax benefits (excluding interest) compared to $ 15,590 as of November 30, 2024 . As of May 31, 2025 and November 30, 2024 , we had accrued $ 3,204 and $ 4,558 of gross interest relating to unrecognized tax benefits, respectively.
Note 10: Earnings Per Share
A reconciliation of the common share components for the basic and diluted earnings per share calculations is as follows:
Three Months Ended
Six Months Ended
May 31,
June 1,
May 31,
June 1,
(Shares in thousands)
2025
2024
2025
2024
Weighted-average common shares - basic
54,443 54,946 54,721 54,824
Equivalent shares from share-based compensations plans
509 1,690 769 1,780
Weighted-average common and common equivalent shares diluted
54,952 56,636 55,490 56,604
Basic earnings per share is calculated by dividing net income attributable to H.B. Fuller by the weighted-average number of common shares outstanding during the applicable period. Diluted earnings per share is based upon the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to share-based compensation awards. We use the treasury stock method to calculate the effect of outstanding shares, which computes total employee proceeds as the sum of (a) the amount the employee must pay upon exercise of the award and (b) the amount of unearned share-based compensation costs attributed to future services. Share-based compensation awards for which total employee proceeds exceed the average market price over the applicable period have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share.
Share-based compensation awards of 2,126,260 and 787,801 shares for the three months ended May 31, 2025 and June 1, 2024 , respectively, were excluded from diluted earnings per share calculations because they were antidilutive. Share-based compensation awards of 2,187,436 and 1,110,664 shares for the six months ended May 31, 2025 and June 1, 2024 , respectively, were excluded from diluted earnings per share calculations because they were antidilutive.
17
Table of Contents
Note 11: Financial Instruments
Overview
As a result of being a global enterprise, foreign currency exchange rates and fluctuations in those rates may affect the Company's net investment in foreign subsidiaries and our earnings, cash flows and financial position are exposed to foreign currency risk from foreign currency denominated receivables and payables.
We use foreign currency forward contracts, cross-currency swaps, interest rate swaps and net investment hedges to manage risks associated with foreign currency exchange rates and interest rates. We do not hold derivative financial instruments of a speculative nature or for trading purposes. We record derivatives as assets and liabilities on the balance sheet at fair value. Changes in fair value are recognized immediately in earnings unless the derivative qualifies and is designated as a hedge. Cash flows from derivatives are classified in the Consolidated Statement of Cash Flows in the same category as the cash flows from the items subject to designated hedge or undesignated (economic) hedge relationships. We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is recorded in earnings.
We are exposed to credit risk in the event of nonperformance of counterparties for foreign currency forward exchange contracts and interest rate swap agreements. We select investment-grade multinational banks and financial institutions as counterparties for derivative transactions and monitor the credit quality of each of these banks on a periodic basis as warranted. We do not anticipate nonperformance by any of these counterparties, and valuation allowances, if any, are de minimis.
Cash Flow Hedges
On January 12, 2023, we entered into an interest rate swap agreement to convert $ 400,000 of our variable rate 1 -month LIBOR debt to a fixed rate of 3.6895 percent that matures on January 12, 2028. On February 28, 2023, after refinancing our debt, we amended t he interest rate swap agreement to our 1 -month SOFR rate debt to a fixed rate of 3.7260 in accordance with the practical expedients included in ASC 848, Reference Rate Reform . The combined fair value of the interest rate swap was a liability of $ 1,554 at May 31, 2025 and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for this interest rate swap. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swap.
On March 16, 2023, we entered into an interest rate swap agreement to convert $ 300,000 of our 1 -month SOFR debt to a fixed rate of 3.7210 percent that matures on February 15, 2028. The combined fair value of the interest rate swap was a liability of $ 1,383 at May 31, 2025 and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical deriv ative method to assess hedge effectiveness for this interest rate swap. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swaps.
On March 16, 2023, we entered into an interest rate swap agreement to convert $ 100,000 of our 1 -month SOFR debt to a fixed rate of 3.8990 percent that matures on February 15, 2028. The combined fair value of the interest rate swap was a liability of $ 870 a t May 31, 2025 and was included i n other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for these interest rate swaps. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swaps.
The amounts of pretax losses recognized in Comprehensive Income related to derivative instruments designated as cash flow hedges are as follows:
Three Months Ended
Six Months Ended
May 31, 2025
June 1, 2024
May 31, 2025
June 1, 2024
Interest rate swap contracts
( 3,206 ) 13,493 ( 4,722 ) 10,217
18
Table of Contents
Fair Value Hedges
On February 12, 2021, we entered into interest rate swap agreements to convert our $ 300,000 Public Notes that were issued on October 20, 2020 to a variable interest rate of 1 -month LIBOR plus 3.28 percent. On June 30, 2023, 1 -month LIBOR rates ceased to exist and the IBOR Fallbacks Protocol published by the International Swaps and Derivatives Association ("ISDA") took effect as outlined in the interest rate swap agreement. As a result, the interest rate swap agreement was converted to Overnight SOFR plus 3.28 percent. We applied the practical expedients included in ASC 848, Reference Rate Reform . These interest rate swap agreements mature on October 15, 2028. The combined fair value of the interest rate swaps wa s a liability of $ 26,864 a t May 31, 2025 , and was included in ot her liabilities i n the Consolidated Balance Sheets. The swaps were designated for hedge accounting treatment as fair value hedges. We apply the short cut method and assume hedge effectiveness. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our $ 300,000 fixed rate Public Notes are compared with the change in the fair value of the swaps.
Net Investment Hedges
On October 17, 2022, we entered into a float-to-float cross-currency interest rate swap agreement with a notional amount of €307,173 maturing in October 2028. On October 20, 2022, we entered into fixed-to-fixed cross-currency interest rate swap agreements for a total notional amount of €300,000 with tranches maturing in August 2025, August 2026 and February 2027. On June 30, 2023, 1 -month LIBOR rates ceased to exist and the IBOR Fallbacks Protocol published by the International Swaps and Derivatives Association (ISDA) took effect as outlined in the interest rate swap agreemen t. As a result, the 1 -month LIBOR leg of the float-to-float agreement was converted to Overnight SOFR plus 3.28 percent. On July 17, 2023, we amended the 1 -month EURIBOR leg of the float-to-float agreement to Overnight ESTR plus 3.2195 percent. We applied the practical expedients included in ASC 848, Reference Rate Reform . As of May 31, 2025 , the combined fair value of the swaps w as a liability of $ 100,366 and was included in other liabilities in the Consol idated Balance Sheets. The cross-currency interest rate swaps hedge a portion of the Company’s investment in Euro denominated foreign subsidiaries.
The swaps are designated as net investment hedges for accounting treatment. The net gains or losses attributable to changes in spot exchange rates are recorded in the cumulative translation adjustment within other comprehensive income. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The amount in accumulated other comprehensive income (loss) related to net investment hedge cross-currency sw aps was a loss of $ 75,936 of May 31, 2025 . The amounts of pretax loss recognized in comprehensive income related to the net investment he dge was $ 60,068 f or the three months ended May 31, 2025 . As of May 31, 2025 , we did not reclassify any gains or losses into earnings from net investment hedges and we do not expect to reclassify any such gain or loss into earnings within the next twelve months. No amounts related to net investment hedges have been excluded from the assessment of hedge effectiveness.
Derivatives Not Designated as Hedging Instruments
We use foreign currency forward contracts to offset our exposure to the change in value of certain foreign currency denominated assets and liabilities held at foreign subsidiaries that are remeasured at the end of each period. Although the contracts are effective economic hedges, they are not designated as accounting hedges. Foreign currency forward contracts are recorded as assets and liabilities on the balance sheet at fair value. Changes in the value of these derivatives are recognized immediately in earnings, thereby offsetting the current earnings effect of the related foreign currency denominated assets and liabilities. See Note 12 for the fair value amounts of these derivative instruments.
As of May 31, 2025 , we had forward foreign currency contracts maturing between June 2, 2025 a nd July 9, 2025. The ma rk-to-market effect associated with these contracts was largely offset by the underlying transaction gains and losses resulting from the foreign currency exposures for which these contracts relate.
The amounts of pre tax gains recognized in other income, net related to derivative instruments not designated as hedging instruments for the six months ended May 31, 2025 and June 1, 2024 wer e $ 3,453 a nd $ 263 , respectively.
Concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of entities in the customer base and their dispersion across many different industries and countries. As of May 31, 2025 , there were no significant concentrations of credit risk.
19
Table of Contents
Note 12: Fair Value Measurements
Overview
Estimates of fair value for financial assets and liabilities are based on the framework established in the accounting guidance for fair value measurements. The framework defines fair value, provides guidance for measuring fair value and requires certain disclosures. The framework discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The framework utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
●
Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
●
Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
●
Level 3: Unobservable inputs that reflect management’s assumptions, and include situations where there is little, if any, market activity for the asset or liability.
Balances Measured at Fair Value on a Recurring Basis
The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis as of May 31, 2025 and November 30, 2024 , and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.
May 31,
Fair Value Measurements Using:
Description
2025
Level 1
Level 2
Level 3
Assets:
Marketable securities
$ 6,011 $ 6,011 $ - $ -
Foreign exchange contract assets
4,281 - 4,281 -
Liabilities:
Foreign exchange contract liabilities
$ 828 $ - 828 $ -
Interest rate swaps, cash flow hedge liabilities
3,807 3,807
Interest rate swaps, fair value hedge liabilities
26,864 - 26,864 -
Net investment hedge liabilities
100,366 - 100,366 -
Holdback liability
32,346 - - 32,346
November 30,
Fair Value Measurements Using:
Description
2024
Level 1
Level 2
Level 3
Assets:
Marketable securities
$ 8,584 $ 8,584 $ - $ -
Foreign exchange contract assets
2,147 - 2,147 -
Interest rate swaps, cash flow hedge assets
1,781 - 1,781 -
Liabilities:
Foreign exchange contract liabilities
$ 7,074 $ - $ 7,074 $ -
Interest rate swaps, cash flow hedge liabilities
265 - 265
Interest rate swaps, fair value hedge liabilities
32,775 - 32,775
Net investment hedge liabilities
51,871 - 51,871 -
20
Table of Contents
The fair value of the holdback liability related to the acquisition of GEM and Medifill, based on a discounted cash flow model, was $ 32,346 as of May 31, 2025. Adjustments to the fair value of the holdback are recorded to interest expense in the Statement of Income. See Note 2 for further discussion regarding our acquisitions. The following table provides details of this Level 3 liability.
Amounts
Balance at November 30, 2024
$ -
Initial valuation of holdback liability
28,922
Interest
382
Foreign currency translation adjustment
3,042
Balance at May 31, 2025
$ 32,346
Balances Measured at Fair Value on a Nonrecurring Basis
We measure certain assets and liabilities at fair value on a nonrecurring basis. These assets include intangible assets acquired in an acquisition. The identified intangible assets of customer relationships, technology and tradenames acquired in connection with our acquisitions were measured using unobservable (Level 3 ) inputs. The fair value of the intangible assets was calculated using either the income or cost approach. Significant inputs include estimated revenue growth rates, gross margins, operating expenses, attrition rate, royalty rate and discount rate.
See Note 2 for further discussion regarding our acquisitions.
Balances Disclosed at Fair Value
Long-term debt had an estimated fair value of $ 1,991,086 and $ 2,015,468 as of May 31, 2025 and November 30, 2024 , respectively. The fair value of long-term debt is based on quoted market prices for the same or similar issues or on the current rates offered for debt of similar maturities. The estimated fair value of these long-term obligations is not necessarily indicative of the amount that would be realized in a current market exchange.
Note 13: Commitments and Contingencies
Environmental Matters
We are involved in environmental investigations, clean-up activities and administrative proceedings related to environmental compliance matters at former and current operating facilities. We have also been identified as a potentially responsible party (“PRP”) under the Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) and/or similar state laws that impose liability for costs relating to the clean-up of contamination resulting from past spills, disposal or other release of hazardous substances associated with landfills and/or hazardous waste sites. As a PRP, we may be required to pay a share of the costs of investigation and clean-up of these sites. We are subject to similar laws in some of the countries where current and former facilities are located. Our environmental, health and safety department monitors compliance with applicable laws on a global basis. To the extent we can reasonably estimate the amount of our probable liabilities for environmental matters, we establish an undiscounted financial provision. We recorded liabilities of $ 3,309 and $ 3,445 as of May 31, 2025 and November 30, 2024 , respectively, for probable and reasonably estimable environmental remediation costs. Of the amount reserved, $ 936 and $ 1,055 as of May 31, 2025 and November 30, 2024 , respectively, is attributable to a facility we own in Simpsonville, South Carolina that is a designated site under CERCLA.
While uncertainties exist with respect to the amounts and timing of the ultimate environmental liabilities, based on currently available information, we have concluded that these matters, individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.
21
Table of Contents
Other Legal Proceedings
From time to time and in the ordinary course of business, we are a party to, or a target of, lawsuits, claims, investigations and proceedings, including product liability, personal injury, contract, patent and intellectual property, environmental, health and safety, tax and employment matters. While we are unable to predict the outcome of these matters, we have concluded, based upon currently available information, that the ultimate resolution of any pending matter, individually or in the aggregate, including the asbestos litigation described in the following paragraphs, will not have a material adverse effect on our results of operations, financial condition or cash flow.
We have been named as a defendant in lawsuits in which plaintiffs have alleged injury due to products containing asbestos manufactured more than 35 years ago. The plaintiffs generally bring these lawsuits against multiple defendants and seek damages (both actual and punitive) in very large amounts. In many cases, plaintiffs are unable to demonstrate that they have suffered any compensable injuries or that the injuries suffered were the result of exposure to products manufactured by us. We are typically dismissed as a defendant in such cases without payment. If the plaintiff presents evidence indicating that compensable injury occurred as a result of exposure to our products, the case is generally settled for an amount that reflects the seriousness of the injury, the length, intensity and character of exposure to products containing asbestos, the number and solvency of other defendants in the case, and the jurisdiction in which the case has been brought.
A significant portion of the defense costs and settlements in asbestos-related litigation is paid by third parties, including indemnification pursuant to the provisions of a 1976 agreement under which we acquired a business from a third party. Currently, this third party is defending and paying settlement amounts, under a reservation of rights, in most of the asbestos cases tendered to the third party.
In addition to the indemnification arrangements with third parties, we have insurance policies that generally provide coverage for asbestos liabilities, including defense costs. Historically, insurers have paid a significant portion of our defense costs and settlements in asbestos-related litigation. However, certain of our insurers are insolvent. We have entered into cost-sharing agreements with our insurers that provide for the allocation of defense costs and settlements and judgments in asbestos-related lawsuits. These agreements require, among other things, that we fund a share of settlements and judgments allocable to years in which the responsible insurer is insolvent.
A summary of the number of and settlement amounts for asbestos-related lawsuits and claims is as follows:
Six Months Ended
3 Years Ended
May 31, 2025
June 1, 2024
November 30, 2024
Lawsuits and claims settled
5 7 25
Settlement amounts
$ 234 $ 1,033 $ 5,704
Insurance payments received or expected to be received
$ 154 $ 730 $ 3,418
We do not believe that it would be meaningful to disclose the aggregate number of asbestos-related lawsuits filed against us because relatively few of these lawsuits are known to involve exposure to asbestos-containing products that we manufactured. Rather, we believe it is more meaningful to disclose the number of lawsuits that are settled and result in a payment to the plaintiff. To the extent we can reasonably estimate the amount of our probable liabilities for pending asbestos-related claims, we establish a financial provision and a corresponding receivable for insurance recoveries.
In February 2024, the named plaintiffs in Rouse et al. v. H.B. Fuller Company et al. filed a third amended complaint in their lawsuit against the Company and one of its subsidiaries, which was initiated in September 2022. The suit is pending in the federal District of Minnesota and seeks damages arising from property damage attributed to alleged defects in grout sold by the Company or its affiliates. The named plaintiffs seek to represent a class but have not yet moved for class certification. The Company intends to vigorously defend itself against the claims outlined in this lawsuit. As of May 31, 2025 , we are unable to estimate any possible loss or range of possible losses and have not recorded a loss contingency for this matter.
Based on currently available information, we have concluded that the resolution of any pending matter, including asbestos-related litigation, individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.
22
Table of Contents
Note 14: Share Repurchase Program
On April 22, 2022, the Board of Directors authorized a share repurchase program of up to $ 300,000 of our outstanding common shares for a period of up to five years. Under the program, we are authorized to repurchase shares for cash on the open market, from time to time, in privately negotiated transactions or block transactions, or through an accelerated repurchase agreement. The timing of such repurchases is dependent on price, market conditions and applicable regulatory requirements. Upon repurchasing shares, we reduce our common stock for the par value of the shares with the excess being applied against additional paid-in capital.
During the second quarter of 2025 , we repurchased shares under this program with an aggregate value of $ 15,777 . Of this amount, $ 300 reduced common stock and $ 15,477 reduced additional paid-in capital. During the six months ended May 31, 2025 , we repurchased shares under this program with an aggregate value of $ 56,930 . Of this amount, $ 978 reduced common stock and $ 55,953 reduced additional paid-in capital.
During the second quarter of 2024 , we repurchased shares under this program with an aggregate value of $ 14,262 . Of this amount, $ 183 reduced common stock and $ 14,079 reduced additional paid-in capital. During the six months ended June 1, 2024 , we repurchased shares under this program with an aggregate value of $ 14,262 . Of this amount, $ 183 reduced common stock and $ 14,079 reduced additional paid-in capital.
Note 15: Segments
We are required to report segment information in the same way that we internally organize our business for assessing performance and making decisions regarding allocation of resources. Revenue and operating income of each of our segments are regularly reviewed by our chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance. Segment operating income is identified as gross profit less SG&A expenses. Corporate expenses, other than those included in Corporate Unallocated, are allocated to each operating segment. Consistent with our internal management reporting, Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning (“ERP”) system that we refer to as Project ONE. Corporate assets are not allocated to the operating segments. Inter-segment revenues are recorded at cost plus a markup for administrative costs.
As of November 30, 2024, our three operating segments consisted of Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. As of the beginning of fiscal 2025, we reorganized our operating segments by selling our North American Flooring business (“NA Flooring”), previously part of the Construction Adhesives operating segment, and combining our Insulated Glass, Woodworking and Composite businesses, previously part of the Engineering Adhesives operating segment, with Construction Adhesives Roofing and Building Envelope and Infrastructure businesses to form the newly named Building Adhesive Solutions operating segment. All financial results related to NA Flooring have been moved to our Corporate Unallocated segment. Prior period segment information has been recast retrospectively to reflect the realignment. Operating results of each of these segments are regularly reviewed by our chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance.
The table below provides certain information regarding net revenue and operating income (loss) for each of our operating segments.
Three Months Ended
May 31, 2025
June 1, 2024
Net
Operating
Net
Operating
Revenue
Income (Loss)
Revenue
Income (Loss)
Hygiene, Health and Consumable Adhesives
$ 397,475 $ 43,401 $ 393,313 $ 49,840
Engineering Adhesives
276,418 46,977 257,613 38,987
Building Adhesive Solutions
224,202 22,114 222,484 21,987
Total segment
$ 898,095 $ 112,492 $ 873,410 $ 110,814
Corporate Unallocated
- ( 12,448 ) 43,697 ( 10,218 )
Total
$ 898,095 $ 100,044 $ 917,107 $ 100,596
Six Months Ended
May 31, 2025
June 1, 2024
Net
Operating
Net
Operating
Revenue
Income (Loss)
Revenue
Income (Loss)
Hygiene, Health and Consumable Adhesives
$ 765,700 $ 73,349 $ 761,391 $ 97,233
Engineering Adhesives
513,177 75,028 483,688 64,807
Building Adhesive Solutions
407,881 28,691 402,150 29,126
Total segment
$ 1,686,758 $ 177,068 $ 1,647,229 $ 191,166
Corporate Unallocated
- ( 30,577 ) 80,296 ( 23,695 )
Total
$ 1,686,758 $ 146,491 $ 1,727,525 $ 167,471
The table below provides a reconciliation of operating income to income before income taxes and income from equity method investments:
Three Months Ended
Six Months Ended
May 31,
June 1,
May 31,
June 1,
2025
2024
2025
2024
Operating income
$ 100,044 $ 100,596 $ 146,491 $ 167,471
Other income, net
7,141 3,634 10,347 5,135
Interest expense
( 34,865 ) ( 32,314 ) ( 66,906 ) ( 64,216 )
Interest income
854 1,199 1,954 2,506
Income before income taxes and income from equity method investments
$ 73,174 $ 73,115 $ 91,886 $ 110,896
The table below provides total assets as of November 30, 2024, restated for our new operating segments:
November 30,
2024
Hygiene, Health and Consumable Adhesives
$ 1,610,902
Engineering Adhesives
1,533,675
Building Adhesive Solutions
1,239,527
Corporate
549,140
Total
$ 4,933,244
23
Table of Contents
We view the following disaggregation of net revenue by geographic region as useful to understanding the composition of revenue recognized during the respective reporting periods:
Three Months Ended May 31, 2025
Hygiene, Health
Building
and Consumable
Engineering
Adhesive
Corporate
Adhesives
Adhesives
Solutions
Unallocated
Total
Americas
$ 228,018 $ 119,161 $ 126,461 $ - $ 473,640
EIMEA
118,238 61,553 82,073 - 261,864
Asia Pacific
51,219 95,704 15,668 - 162,591
Total
$ 397,475 $ 276,418 $ 224,202 $ - $ 898,095
Three Months Ended June 1, 2024
Hygiene, Health
Building
and Consumable
Engineering
Adhesive
Corporate
Adhesives
Adhesives
Solutions
Unallocated
Total
Americas
$ 227,671 $ 106,570 $ 119,975 $ 43,697 $ 497,913
EIMEA
112,314 60,354 86,357 - 259,025
Asia Pacific
53,328 90,689 16,152 - 160,169
Total
$ 393,313 $ 257,613 $ 222,484 $ 43,697 $ 917,107
Six Months Ended May 31, 2025
Hygiene, Health
Building
and Consumable
Engineering
Adhesive
Corporate
Adhesives
Adhesives
Solutions
Unallocated
Total
Americas
$ 435,372 $ 216,370 $ 222,161 $ - $ 873,903
EIMEA
229,005 111,816 157,236 - 498,057
Asia Pacific
101,323 184,991 28,484 - 314,798
Total
$ 765,700 $ 513,177 $ 407,881 $ - $ 1,686,758
Six Months Ended June 1, 2024
Hygiene, Health
Building
and Consumable
Engineering
Adhesive
Corporate
Adhesives
Adhesives
Solutions
Unallocated
Total
Americas
$ 445,057 $ 194,646 $ 209,215 $ 80,296 $ 929,214
EIMEA
215,567 114,887 162,937 - 493,391
Asia Pacific
100,767 174,155 29,998 - 304,920
Total
$ 761,391 $ 483,688 $ 402,150 $ 80,296 $ 1,727,525
24
Table of Contents
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.